Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M101Revenue $M11.3Net Margin (%)-183.1Altman Z-Score-8.9
Enterprise Value $M46.9EPS $-0.4Operating Margin %-191.7Piotroski F-Score2
P/E(ttm)--Beneish M-Score-2.4Pre-tax Margin (%)-183.1Higher ROA y-yN
Price/Book2.810-y EBITDA Growth Rate %-12.8Quick Ratio3.3Cash flow > EarningsN
Price/Sales9.05-y EBITDA Growth Rate %-14.3Current Ratio3.3Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-29.0Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-46.4Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M62.8ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with ARQL

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ARQLFirst Eagle Investment 2015-03-31 Add0.01%$1.1 - $2.46
($1.59)
$ 1.622%Add 28.69%5,719,968
ARQLFirst Eagle Investment 2014-12-31 Add$1.06 - $1.36
($1.18)
$ 1.6237%Add 56.31%4,444,899
ARQLGeorge Soros 2014-09-30 Sold Out $1.12 - $1.56
($1.31)
$ 1.6224%Sold Out0
ARQLGeorge Soros 2014-06-30 Buy $1.34 - $2.04
($1.56)
$ 1.624%New holding78,600
ARQLFirst Eagle Investment 2013-09-30 Reduce-0.01%$2.15 - $2.79
($2.51)
$ 1.62-35%Reduce 26.47%3,314,553
ARQLFirst Eagle Investment 2012-12-31 Add0.01%$2.18 - $2.95
($2.6)
$ 1.62-38%Add 49.46%4,539,651
ARQLFirst Eagle Investment 2012-06-30 Add0.01%$5.53 - $8.16
($6.56)
$ 1.62-75%Add 28.79%2,673,589
ARQLGeorge Soros 2011-12-31 Sold Out -0.0014%$4.58 - $6.05
($5.55)
$ 1.62-71%Sold Out0
ARQLGeorge Soros 2011-09-30 Add$4.11 - $6.64
($5.2)
$ 1.62-69%Add 54.79%16,100
ARQLFirst Eagle Investment 2011-03-31 Add0.03%$5.85 - $6.95
($6.41)
$ 1.62-75%Add 84.22%1,693,456
ARQLGeorge Soros 2011-03-31 Buy $5.85 - $6.95
($6.41)
$ 1.62-75%New holding12,200
ARQLFirst Eagle Investment 2010-12-31 Add0.01%$4.95 - $6.14
($5.53)
$ 1.62-71%Add 29.43%919,266
ARQLFirst Eagle Investment 2010-03-31 Reduce-0.02%$3.04 - $3.92
($3.45)
$ 1.62-53%Reduce 56.47%685,266
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ARQL is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


ARQL: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
ZENNER PATRICK JDirector 2015-03-11Buy10,625$2.32-30.17view
Pucci PaoloCEO 2014-11-20Buy5,000$1.2628.57view
ZENNER PATRICK JDirector 2014-11-14Buy20,830$1.235view
Messenger William GDirector 2014-11-14Buy8,500$1.2133.88view
Kelley Susan L.Director 2014-11-13Buy50,000$1.235view
Pucci PaoloCEO 2014-09-04Buy5,000$1.3123.66view
Pucci PaoloCEO 2014-05-23Buy5,000$1.415.71view
Pucci PaoloCEO 2014-05-20Buy5,000$1.4214.08view
ZENNER PATRICK JDirector 2014-03-17Buy4,715$2.12-23.58view
Pucci PaoloCEO 2014-03-13Buy10,000$2.1-22.86view

Quarterly/Annual Reports about ARQL:

News about ARQL:

Articles On GuruFocus.com
Jean-Marie Eveillard Increases Stakes in Cancer Therapeutics Company Arqule Inc May 05 2015 
Jean-Marie Eveillard Adds to Stake in Arqule Inc. May 03 2015 
comment on ARQL Nov 29 2012 
ArQule Inc. Reports Operating Results (10-Q) Nov 09 2010 
ArQule Inc. Reports Operating Results (10-Q) Aug 04 2010 
ArQule Inc. Reports Operating Results (10-Q) May 06 2010 
cooldecency99 note on ARQL May 01 2010 
ArQule Inc. (ARQL) CEO Paolo Pucci buys 5,000 Shares Nov 13 2009 
ArQule Inc. Reports Operating Results (10-Q) Aug 07 2009 
ArQule Reports Second Quarter 2009 Financial Results Aug 06 2009 

More From Other Websites
ARQULE INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Jun 01 2015
ArQule Appoints Robert J. Weiskopf as Chief Financial Officer Jun 01 2015
ArQule Announces Data Presentations with Tivantinib and ARQ 087 to Be Featured at ASCO 2015 May 29 2015
ArQule Announces Data Presentations with Tivantinib and ARQ 087 to Be Featured at ASCO 2015 May 29 2015
ArQule, Inc. to Present at Jefferies 2015 Global Healthcare Conference May 27 2015
ArQule, Inc. to Present at Jefferies 2015 Global Healthcare Conference May 27 2015
ARQULE INC Financials May 15 2015
ARQULE INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 13 2015
10-Q for ArQule, Inc. May 08 2015
ARQULE INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and... May 07 2015
ARQULE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... May 06 2015
ArQule Reports First Quarter 2015 Financial Results May 06 2015
ArQule reports 1Q loss May 06 2015
ArQule reports 1Q loss May 06 2015
Q1 2015 ArQule Inc Earnings Release - 07:00 am ET May 06 2015
ArQule Reports First Quarter 2015 Financial Results May 06 2015
ArQule and Beryllium Announce Collaborative Research and Development Agreement May 05 2015
ArQule and Beryllium Announce Collaborative Research and Development Agreement May 05 2015
3 Biotech Stocks With Big Phase 3 Catalyst Data Due in 2015 May 01 2015
ArQule to Report First Quarter 2015 Financial Results on May 6, 2015 Apr 29 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK